Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 0.98 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.98 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.98 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.98 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | PTGES | O14684 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL3518614 | 0.99 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29353712 | 0.99 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9300 | 0.99 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29525957 | 0.99 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23632959 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL8352438 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL1817813 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL22472310 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL3860125 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23391006 | 0.98 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1160129-C | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | 王 晓 | 2004-08-04 | — | — | CN | claimed |
| CN-1166963-A | Composition containing zinc compound and p-acetaminophenyl acetic acid | XIA XIAOLIN (CN) | 1997-12-10 | — | — | CN | claimed |
| CN-1166320-A | Composite of zinc containing compound and glutamines | XIA XIAOLIN (CN) | 1997-12-03 | — | — | CN | claimed |
| CN-101474197-B | Application of coumpound baicalin-zinc in preparing medicament for resisting peptic ulcer | KUNMING MEDICAL COLLEGE | 2011-04-06 | — | — | CN | disclosed |
| CN-101474197-A | Application of coumpound baicalin-zinc in preparing medicament for resisting peptic ulcer | KUNMING MEDICAL COLLEGE (CN) | 2009-07-08 | — | — | CN | disclosed |
| US-20080039522-A1 | Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity | MEDICAL THERAPIES LIMITED (AU) | 2008-02-14 | — | — | US | disclosed |
| WO-2007109845-A1 | PROPHYLAXIS OR TREATMENT OF DIABETES | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110755-A1 | PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR INFLAMMATION | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110745-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| EP-1734945-A4 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | MEDICAL THERAPIES LTD (AU) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007026240-A1 | SUNSCREEN AND COSMETIC COMPOSITIONS FOR PROPHYLAXIS OR TREATMENT OF SKIN CANCERS | MEDICAL THERAPIES LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| EP-1734945-A1 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | THE UNIVERSITY OF SYDNEY (AU) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006099685-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CARCINOMAS | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | disclosed |
| CN-1265799-C | Composite of zinc containing compound and glutamines | XIA XIAOLIN (CN) | 2006-07-26 | — | — | CN | disclosed |
| WO-2005094809-A1 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | MEDICAL THERAPIES LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |
| CN-1076195-C | Composition containing zinc compound and p-acetaminophenyl acetic acid | XIA XIAOLIN (CN) | 2001-12-19 | — | — | CN | disclosed |
| CN-1166963-A | Composition containing zinc compound and p-acetaminophenyl acetic acid | XIA XIAOLIN (CN) | 1997-12-10 | — | — | CN | disclosed |
| CN-1166320-A | Composite of zinc containing compound and glutamines | XIA XIAOLIN (CN) | 1997-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039522-A1 | Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity | MIF, TNF, LITAF | PTGS2 280/4885PTGS1 150/4885AKR1C3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.